Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.36 |
| ▸ | RAB9A | P51151 | 7/20 | 0.36 |
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | CIT | O14578 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127145 | 0.85 | KCNH2 (0.44) | KCNH2EGFRRIPK2SMN1; SMN2RAB9A | |
| SCHEMBL3887751 | 0.83 | KCNH2 (0.42) | KCNH2EGFRRIPK2MAPTGAA | |
| SCHEMBL1871665 | 0.81 | RIPK2 (0.38) | KCNH2EGFRRIPK2NR1I2BRAF | |
| SCHEMBL29039421 | 0.81 | KCNH2 (0.62) | KCNH2EGFRSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL30410044 | 0.81 | KCNH2 (0.62) | KCNH2EGFRSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2193545 | 0.80 | RIPK2 (0.53) | KCNH2RIPK2NR1I2BRAFAR | |
| SCHEMBL1888596 | 0.79 | BRAF (0.45) | KCNH2EGFRRIPK2BRAF | |
| SCHEMBL2190892 | 0.79 | BRAF (0.51) | KCNH2RIPK2NR1I2BRAFLCK | |
| SCHEMBL1127477 | 0.79 | KCNH2 (0.37) | KCNH2EGFRRIPK2MAPTALOX15 | |
| SCHEMBL1126967 | 0.78 | AR (0.43) | KCNH2EGFRRIPK2SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011059610-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059610-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-2282636-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | KCNH2 1701/4885EGFR 2172/4885RIPK2 2125/4885 |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | KCNH2 1701/4885EGFR 2172/4885RIPK2 2125/4885 |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | KCNH2 1701/4885EGFR 2172/4885RIPK2 2125/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | KCNH2 1701/4885EGFR 2172/4885RIPK2 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.